ArticleMolecular diversity2026
Synthesis and antifungal and antitumor activities of acridine-containing tetrahydronaphthalene spiroisoxazoline derivatives.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To develop novel functional molecules with both antifungal and antitumor activities, this study rationally designed and synthesized 11 acridine-containing tetrahydronaphthalene spiroisoxazoline derivatives based on the bioactive fragment characteristics of isoxazoline, acridine, tetrahydronaphthalene, and spirocycle moieties. Using o-aminoacetophenone and other reagents as starting materials, the target compounds were prepared via a multi-step synthetic route involving copper-catalyzed Ullmann coupling, Wittig reaction, and Huisgen cycloaddition. The results of biological activity assays demonstrated that these compounds exerted definite antifungal effects against a variety of fungi, especially Ampelomyces humuli. Among them, compound 10a displayed the half-maximal effective concentration value of 0.9768 µg/mL against Ampelomyces humuli, which was superior to that of the positive controls Chlorothalonil (1.767 µg/mL), Famoxadone (13.87 µg/mL), and Carbendazim (27.02 µg/mL). The mycelial growth rate method indicated that its inhibitory effect on the mycelial growth of Ampelomyces humuli was concentration-dependent. Fluorescence staining experiments revealed that this compound could induce damage to fungal cell membranes and inhibit fungal spore secretion. In vitro experiments confirmed that it possessed certain protective and curative effects on corn leaves infected by Ampelomyces humuli. In addition, cytotoxicity studies showed that these compounds exhibited relatively high toxicity against normal cells while exerting significant antiproliferative activity against human colorectal cancer cells; notably, compound 10e had the half-maximal inhibitory concentration value of 2.53 µM, which was higher than that of the positive controls Cisplatin (36.00 µM) and Doxorubicin (10.43 µM). These findings suggest that the novel acridine-containing tetrahydronaphthalene spiroisoxazoline derivatives with multiple active fragments hold promise as candidates for the development of new antifungal agents and antitumor drugs.
Indexed as
Identifiers
41879900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.